Breakthrough in Glioblastoma Treatment: Immuncell-LC Therapy Extends Survival by Nearly Six Months in Phase 3 Trial

Immunotherapy Shows Promise in Phase 3 Glioblastoma Trial

GC Cell Corporation has announced positive results from its Phase 3 clinical trial of Immuncell-LC, an activated T lymphocyte therapy, in combination with temozolomide for newly diagnosed glioblastoma. The study demonstrated significant improvements in both progression-free survival and overall survival compared to standard treatment.

Significant Survival Benefits: How Much Difference Did Immuncell-LC Make?

The randomized, open-label, multi-center trial conducted in South Korea enrolled 180 patients with newly diagnosed glioblastoma who were treated with either standard temozolomide plus radiation therapy alone (control group, n=89) or with the addition of Immuncell-LC (test group, n=91). Results showed that patients receiving Immuncell-LC achieved a median progression-free survival of 8.1 months compared to 5.4 months in the control group. More importantly, the median overall survival reached 22.47 months in the Immuncell-LC group versus 16.88 months with standard care alone.

Behind the Treatment: Mechanism and Protocol Design

Immuncell-LC is designed to remove minimal residual cancer cells after brain tumor removal and prevent relapse. The treatment involves drawing the patient's blood to manufacture the personalized therapy, which is then administered intravenously over one hour, containing approximately 10^9-2x10^10 lymphocytes per dose.

The study protocol included surgery for glioblastoma followed by temozolomide chemotherapy and radiation therapy for 6 weeks in both groups. The test group additionally received 14 doses of Immuncell-LC. Patient characteristics were well-balanced between the groups, with a median age of 55 years in the test group and 54 years in the control group.

Safety Profile: How Did Patients Tolerate the Therapy?

Safety data showed similar profiles between the two groups. Serious adverse events occurred in 38.5% of patients in the test group compared to 34.8% in the control group. The most common serious adverse events were neurological, including convulsions, headaches, and brain edema. Deaths occurred in 56% of the test group and 58.4% of the control group, reflecting the aggressive nature of glioblastoma.

Clinical Impact: What This Means for Glioblastoma Care

The trial, which ran from December 2008 to October 2012, represents a significant advancement in glioblastoma treatment, one of the most aggressive forms of brain cancer. The results were recently posted on ClinicalTrials.gov (October 10, 2025) after undergoing quality control review.

This completed study demonstrates the potential for immunotherapeutic approaches to extend survival in glioblastoma, a disease area with limited treatment options and historically poor outcomes. The nearly six-month improvement in overall survival may represent a meaningful clinical benefit for patients with this devastating diagnosis.

Summary

A Phase 3 clinical trial conducted by GC Cell Corporation in South Korea has demonstrated that adding Immuncell-LC, a personalized activated T lymphocyte therapy, to standard temozolomide and radiation therapy significantly improves outcomes for newly diagnosed glioblastoma patients. The study of 180 patients showed that the Immuncell-LC group achieved a median progression-free survival of 8.1 months versus 5.4 months in the control group, and more importantly, median overall survival reached 22.47 months compared to 16.88 months with standard care alone. Safety profiles were similar between groups, with serious adverse events occurring in 38.5% of patients in the test group versus 34.8% in the control group. This advancement represents a meaningful clinical benefit for patients with this aggressive form of brain cancer.